{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T06:30:29Z","timestamp":1777617029120,"version":"3.51.4"},"reference-count":24,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2018,3,12]],"date-time":"2018-03-12T00:00:00Z","timestamp":1520812800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Medical Virology"],"published-print":{"date-parts":[[2018,6]]},"abstract":"<jats:sec><jats:label\/><jats:p>The presence of resistance\u2010associated substitutions (RASs) at NS5A region might compromise the efficacy of Direct Acting Antiviral agents (DAAs). HCV resistance at NS5A region is mainly focused on patients with hepatitis C virus (HCV) genotypes 1a (G1a) and 3 (G3) with other factors of poor treatment response (ie cirrhosis, prior treatment\u2010exposure, or HCV\u2010RNA &gt;800\u2009000\u2009IU\/mL). Herein, we evaluated in a cohort of HCV G1a and G3 infected patients the prevalence of RASs at domain I NS5A using population\u2010based sequencing and the impact of RASs on the optimization of current therapeutic strategies. The RASs considered as clinically relevant were: M28A\/G\/T, Q30D\/E\/H\/G\/K\/L\/R, L31M\/V\/F, H58D, and Y93C\/H\/N\/S for G1a and Y93H for G3. A total of 232 patients na\u00efve to NS5A inhibitors were included (166 G1a, 66 G3). The overall prevalence of NS5A RASs for G1a and G3 patients was low (5.5%) or null, respectively. A high proportion of patients harbored, at least, one factor of poor response (78.9% for G1a, and 75.8% for G3). Overall, the rates of patients harboring NS5A RASs in combination with any of the other factors were low and the vast majority of patients (G1a&gt;\u200994% and G3 100%) could be treated with standard treatments of 12 weeks without ribavirin. In conclusion, testing NS5A RASs in specific HCV\u2010infected populations (ie G1a &amp; G3, cirrhosis, prior treatment experienced, HCV\u2010RNA &gt;800\u2009000\u2009IU\/mL) might be useful to optimize current NS5A\u2010based therapies avoiding ribavirin\u2010related toxicities, and shortening treatment duration in the majority of patients.<\/jats:p><\/jats:sec>","DOI":"10.1002\/jmv.25048","type":"journal-article","created":{"date-parts":[[2018,2,10]],"date-time":"2018-02-10T12:42:37Z","timestamp":1518266557000},"page":"1094-1098","source":"Crossref","is-referenced-by-count":8,"title":["Prevalence of NS5A resistance associated substitutions in patients with hepatitis C virus genotypes 1a and 3: Impact on current therapeutic strategies"],"prefix":"10.1002","volume":"90","author":[{"given":"Marta","family":"Grandal","sequence":"first","affiliation":[{"name":"Grupo de Virolog\u00eda Cl\u00ednica, Instituto de Investigaci\u00f3n Biom\u00e9dica de A Coru\u00f1a (INIBIC)\u2010Complexo Hospitalario Universitario de A Coru\u00f1a (CHUAC) Sergas. Universidade da Coru\u00f1a (UDC) A Coru\u00f1a Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Berta","family":"Pernas","sequence":"additional","affiliation":[{"name":"Grupo de Virolog\u00eda Cl\u00ednica, Instituto de Investigaci\u00f3n Biom\u00e9dica de A Coru\u00f1a (INIBIC)\u2010Complexo Hospitalario Universitario de A Coru\u00f1a (CHUAC) Sergas. Universidade da Coru\u00f1a (UDC) A Coru\u00f1a Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9s","family":"Tabernilla","sequence":"additional","affiliation":[{"name":"Grupo de Virolog\u00eda Cl\u00ednica, Instituto de Investigaci\u00f3n Biom\u00e9dica de A Coru\u00f1a (INIBIC)\u2010Complexo Hospitalario Universitario de A Coru\u00f1a (CHUAC) Sergas. Universidade da Coru\u00f1a (UDC) A Coru\u00f1a Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Mari\u00f1o","sequence":"additional","affiliation":[{"name":"Unidad de Enfermedades Infecciosas Servicio de Medicina Interna Complexo Hospitalario Universitario de Ferrol (CHUF), Sergas Ferrol Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hortensia","family":"\u00c1lvarez","sequence":"additional","affiliation":[{"name":"Unidad de Enfermedades Infecciosas Servicio de Medicina Interna Complexo Hospitalario Universitario de Ferrol (CHUF), Sergas Ferrol Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nieves","family":"Valcarce","sequence":"additional","affiliation":[{"name":"Unidad de Enfermedades Infecciosas Servicio de Medicina Interna Complexo Hospitalario Universitario de Ferrol (CHUF), Sergas Ferrol Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alvaro","family":"Mena","sequence":"additional","affiliation":[{"name":"Grupo de Virolog\u00eda Cl\u00ednica, Instituto de Investigaci\u00f3n Biom\u00e9dica de A Coru\u00f1a (INIBIC)\u2010Complexo Hospitalario Universitario de A Coru\u00f1a (CHUAC) Sergas. Universidade da Coru\u00f1a (UDC) A Coru\u00f1a Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angeles","family":"Castro\u2010Iglesias","sequence":"additional","affiliation":[{"name":"Grupo de Virolog\u00eda Cl\u00ednica, Instituto de Investigaci\u00f3n Biom\u00e9dica de A Coru\u00f1a (INIBIC)\u2010Complexo Hospitalario Universitario de A Coru\u00f1a (CHUAC) Sergas. Universidade da Coru\u00f1a (UDC) A Coru\u00f1a Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana B.","family":"P\u00e9rez","sequence":"additional","affiliation":[{"name":"Servicio de Microbiolog\u00eda Cl\u00ednica Instituto de Investigaci\u00f3n IBS Granada Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Delgado","sequence":"additional","affiliation":[{"name":"Grupo de Virolog\u00eda Cl\u00ednica, Instituto de Investigaci\u00f3n Biom\u00e9dica de A Coru\u00f1a (INIBIC)\u2010Complexo Hospitalario Universitario de A Coru\u00f1a (CHUAC) Sergas. Universidade da Coru\u00f1a (UDC) A Coru\u00f1a Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4835-9875","authenticated-orcid":false,"given":"Eva","family":"Poveda","sequence":"additional","affiliation":[{"name":"Grupo de Virolog\u00eda Cl\u00ednica, Instituto de Investigaci\u00f3n Biom\u00e9dica de A Coru\u00f1a (INIBIC)\u2010Complexo Hospitalario Universitario de A Coru\u00f1a (CHUAC) Sergas. Universidade da Coru\u00f1a (UDC) A Coru\u00f1a Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,3,12]]},"reference":[{"key":"e_1_2_7_2_1","unstructured":"AASLD\u2010IDSA Guidance Panel.2017. HCV guidance: recommendations for testing managing and treating hepatitis C.http:\/\/www.hcvguidelines.org(accessed 21.09.17)."},{"key":"e_1_2_7_3_1","first-page":"153","article-title":"EASL Recommendations on Treatment of Hepatitis C","volume":"66","year":"2016","journal-title":"J Hepatol"},{"key":"e_1_2_7_4_1","unstructured":"AEEH\/SEIMC 2017. Gu\u00edas de manejo de la hepatitis C.http:\/\/aeeh.es\/wp\u2010content\/uploads\/2017\/03\/documento\u2010consenso.pdf. (accessed 20.05.17)."},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1512612"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.06.002"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27726"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(15)31094-1"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.11.022"},{"key":"e_1_2_7_10_1","first-page":"254A","article-title":"Prevalence of pretreatment NS5A resistance associated variants in genotype 1 patients across different regions using deep sequencing and effect on treatment outcome with LDV\/SOF","volume":"62","author":"Zeuzem S","year":"2015","journal-title":"Hepatology"},{"key":"e_1_2_7_11_1","first-page":"554A","article-title":"Predictors response to grazoprevir\/elbasvir among HCV genotype 1 (GT1)\u2010infected patients: integrated analysis of Phase 2\u20103 trials","volume":"62","author":"Zeuzem S","year":"2015","journal-title":"Hepatology"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.01.007"},{"key":"e_1_2_7_13_1","first-page":"47","article-title":"News on viral hepatitis in HIV: update from the 2016 GEHEP conference","volume":"19","author":"Poveda E","year":"2017","journal-title":"AIDS Rev"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2014.05.015"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.3851\/IMP2091"},{"key":"e_1_2_7_16_1","first-page":"6","article-title":"CO\u201012: Nuevos antivirales de acci\u00f3n directa frente al virus de la hepatitis C: prevalencia basal de sustituciones asociadas a menor tasa de respuesta viral sostenida","volume":"3","author":"P\u00e9rez AB","year":"2016","journal-title":"Enferm Infecc y Microbiol Clin"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0155869"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.04.003"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0134395"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.3109\/23744235.2015.1028097"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1186\/1743-422X-10-355"},{"key":"e_1_2_7_22_1","first-page":"15","article-title":"NS5A resistance: clinical implications and treatment possibilities","volume":"18","author":"Calleja JL","year":"2016","journal-title":"AIDS Rev"},{"key":"e_1_2_7_23_1","first-page":"30126","article-title":"[Prevalence of relevant NS5A resistance\u2010Associated substitutions to elbasvir in genotype 1a hepatitis C virus patients in Spain]","author":"Palladino C","year":"2017","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.3390\/v8040091"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep20310"}],"container-title":["Journal of Medical Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjmv.25048","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jmv.25048","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T06:50:38Z","timestamp":1695538238000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jmv.25048"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,12]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["10.1002\/jmv.25048"],"URL":"https:\/\/doi.org\/10.1002\/jmv.25048","archive":["Portico"],"relation":{},"ISSN":["0146-6615","1096-9071"],"issn-type":[{"value":"0146-6615","type":"print"},{"value":"1096-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,12]]}}}